Clinical Trial Search

Primary: Area Under the Plasma Concentration-Time Curve From Zero to Tau at Steady State (AUCt,ss) of Ethinyl Estradiol and Levonorgestrel — 789; 817; 91400; 92000 hour*picograms…

Primary: Percentage of Subjects With Drug Related Adverse Events — 16.7; 16.7; 33.3; 0.0 percentage of participants

Primary: Mean Diurnal IOP at Month 3 — 17.5; 16.8 mmHg

Primary: Degree of Disability/Dependence as Measured by the Modified Rankin Scale (mRS) Score — 4; 5 scores on a scale

Primary: Pharmacokinetics ASNase Activity >100 U/L at 14 Days — 92.5 percentage of patients

Primary: Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12. — 30.8; 22.4; 35.1 percentage of participants — p=0.1321

Primary: Number of Participants With Treatment-related Adverse Events (TEAEs) For ALXN1820 SC And ALXN1820 IV — 1; 0; 0; 4 Participants

Primary: Gait Kinematic Response for 180 and 60Hz DBS — 27.37; 29.05; 25.68; 28.31 units on a scale — p=<0.05

Primary: Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight — -0.31; -0.42 kg/40mg IV furosemide

Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-07284890 in Plasma, Comparison of…

Primary: Overall Survival (OS) — 11.1; 9.2 months — p=0.04

Primary: Time From Randomization to the First Component Event of Major Adverse Cardiac Event (MACE): Number and Percentage of Participants With an Event — 182; 190 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase 1b — 0; 0; 0; 0 Participants

Primary: Number of Participants With Pathologic Complete Response (pCR) — 11 Participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by Liver Function Tests — 0; 0; 0; 2 Participants